Long-term results of low-dose tissue plasminogen activator therapy in acute pulmonary embolism

被引:3
作者
Hezer, Habibe [1 ]
Kilic, Hatice [2 ]
Abuzaina, Osama [2 ]
Hasanoglu, H. Canan [2 ]
Karalezli, Aysegul [2 ]
机构
[1] Ankara Ataturk Training & Res Hosp, Dept Pulm Dis, TR-06800 Ankara, Turkey
[2] Ankara Yildirim Beyazit Univ, Dept Pulm Dis, Fac Med, Ankara, Turkey
关键词
low dose; pulmonary embolism; thrombolytic therapy; tissue plasminogen activator (Rt-PA); THROMBOLYTIC THERAPY; ANTITHROMBOTIC THERAPY; ALTEPLASE; MULTICENTER; HEPARIN; RISK; EFFICACY; INFUSION; BOLUS;
D O I
10.1136/jim-2019-001042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant tissue plasminogen activator (rt-PA) is the most commonly used thrombolytic agent in patients with high risk and intermediate to high mortality risk acute pulmonary embolism (PE). Clinical trials have shown early efficacy and safety of low-dose rt-PA. This study investigated the effects of low-dose rt-PA treatment on acute PE in long-term prognosis, recurrence of pulmonary thromboembolism, or the development of late complications. In this study, 48 patients undergoing low-dose rt-PA for the relative contraindications of thrombolytic therapy and 48 patients undergoing standard-dose therapy were evaluated retrospectively. Long-term follow-up investigated the chronic PE, recurrence, and causes of morbidity and mortality. In both treatment groups, embolism-induced mortality and overall mortality rates were similar in the first 30 days (p=1.000, p=0.714, respectively). Overall mortality rates in long-term follow-up were 41.7% in the low-dose treatment group and 16.7% in the standard-dose treatment group (p=0.013). The mortality rate at the first year was higher in the low-dose-treated group (p=0.011) and most of the deaths were due to accompanying comorbidities. There was no difference in PE recurrence and duration of recurrence between the groups (p=0.598, p=0.073, respectively). Intracranial hemorrhage due to therapy developed in one patient in both groups. Low-dose thrombolytic therapy in acute PE reduces PE-related mortality in the early period. Long-term follow-up showed that thrombolytic therapy did not affect mortality rates independently of the dose and PE recurrence.
引用
收藏
页码:1142 / 1147
页数:6
相关论文
共 22 条
  • [1] Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction
    Berkowitz, SD
    Granger, CB
    Peiper, KS
    Lee, KL
    Gore, JM
    Simoons, M
    Armstrong, PW
    Topol, EJ
    Califf, RM
    [J]. CIRCULATION, 1997, 95 (11) : 2508 - 2516
  • [2] Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism
    Brandt, Kimberly
    McGinn, Kaitlin
    Quedado, Jeffrey
    [J]. ANNALS OF PHARMACOTHERAPY, 2015, 49 (07) : 818 - 824
  • [3] Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis
    Chatterjee, Saurav
    Chakraborty, Anasua
    Weinberg, Ido
    Kadakia, Mitul
    Wilensky, Robert L.
    Sardar, Partha
    Kumbhani, Dharam J.
    Mukherjee, Debabrata
    Jaff, Michael R.
    Giri, Jay
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23): : 2414 - 2421
  • [4] Heart Disease and Stroke Statistics-2013 Update A Report From the American Heart Association
    Go, Alan S.
    Mozaffarian, Dariush
    Roger, Veronique L.
    Benjamin, Emelia J.
    Berry, Jarett D.
    Borden, William B.
    Bravata, Dawn M.
    Dai, Shifan
    Ford, Earl S.
    Fox, Caroline S.
    Franco, Sheila
    Fullerton, Heather J.
    Gillespie, Cathleen
    Hailpern, Susan M.
    Heit, John A.
    Howard, Virginia J.
    Huffman, Mark D.
    Kissela, Brett M.
    Kittner, Steven J.
    Lackland, Daniel T.
    Lichtman, Judith H.
    Lisabeth, Lynda D.
    Magid, David
    Marcus, Gregory M.
    Marelli, Ariane
    Matchar, David B.
    McGuire, Darren K.
    Mohler, Emile R.
    Moy, Claudia S.
    Mussolino, Michael E.
    Nichol, Graham
    Paynter, Nina P.
    Schreiner, Pamela J.
    Sorlie, Paul D.
    Stein, Joel
    Turan, Tanya N.
    Virani, Salim S.
    Wong, Nathan D.
    Woo, Daniel
    Turner, Melanie B.
    [J]. CIRCULATION, 2013, 127 (01) : E6 - E245
  • [5] ALTEPLASE VERSUS HEPARIN IN ACUTE PULMONARY-EMBOLISM - RANDOMIZED TRIAL ASSESSING RIGHT-VENTRICULAR FUNCTION AND PULMONARY PERFUSION
    GOLDHABER, SZ
    HAIRE, WD
    FELDSTEIN, ML
    MILLER, M
    TOLTZIS, R
    SMITH, JL
    DASILVA, AMT
    COME, PC
    LEE, RT
    PARKER, JA
    MOGTADER, A
    MCDONOUGH, TJ
    BRAUNWALD, E
    [J]. LANCET, 1993, 341 (8844) : 507 - 511
  • [6] REDUCED DOSE BOLUS ALTEPLASE VS CONVENTIONAL ALTEPLASE INFUSION FOR PULMONARY-EMBOLISM THROMBOLYSIS - AN INTERNATIONAL MULTICENTER RANDOMIZED TRIAL
    GOLDHABER, SZ
    AGNELLI, G
    LEVINE, MN
    [J]. CHEST, 1994, 106 (03) : 718 - 724
  • [7] Thrombolytic therapy for pulmonary embolism
    Hao, Qiukui
    Dong, Bi Rong
    Yue, Jirong
    Wu, Taixiang
    Liu, Guan J.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [8] Hasanoglu HC, 2014, J INVEST MED, V62, P71, DOI 10.2310/JIM.0000000000000014
  • [9] Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
    Kearon, Clive
    Akl, Elie A.
    Ornelas, Joseph
    Blaivas, Allen
    Jimenez, David
    Bounameaux, Henri
    Huisman, Menno
    King, Christopher S.
    Morris, Timothy A.
    Sood, Namita
    Stevens, Scott M.
    Vintch, Janine R. E.
    Wells, Philip
    Woller, Scott C.
    Moores, Lisa
    [J]. CHEST, 2016, 149 (02) : 315 - 352
  • [10] Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
    Kearon, Clive
    Akl, Elie A.
    Comerota, Anthony J.
    Prandoni, Paolo
    Bounameaux, Henri
    Goldhaber, Samuel Z.
    Nelson, Michael E.
    Wells, Philip S.
    Gould, Michael K.
    Dentali, Francesco
    Crowther, Mark
    Kahn, Susan R.
    [J]. CHEST, 2012, 141 (02) : E419S - +